Hong Kong Market Wrap: Hang Seng Falls 0.91%, Tech Index Down 0.58%, Internet and Gold Stocks Decline Broadly, Application Software Sector Rallies in Afternoon, Zhipu Surges Over 9%

Deep News11-18 16:21

The three major Hong Kong stock indices all declined collectively. As of the close, the Hang Seng Index fell 0.91% to 23,294.75, the Hang Seng Tech Index dropped 0.58%, and the China Enterprises Index slipped 0.86%.

On the board, internet stocks fell broadly, with JD.com down over 7% and Bilibili down more than 2%. The application software sector rallied in the afternoon, with Zhipu surging over 9%. Gold stocks led the declines, with Lingbao Gold dropping more than 6%. Innovative drug concept stocks weakened, with Akeso Biopharma falling over 4%.

The application software sector rallied in the afternoon, with Zhipu surging over 9%. Nvidia released its earnings report after the U.S. market close on Tuesday, reporting Q3 revenue of $115.8 billion for fiscal year 2027, exceeding market expectations of $109.1 billion. Q3 net profit reached $65.3 billion, beating market expectations of $60.406 billion. The company projected fourth-quarter revenue of $130 billion, above the analyst average estimate of $125.25 billion. Additionally, market participants noted that domestic market demand plays a prominent role in supporting technology enterprises, particularly in computing infrastructure, industrial software, and smart manufacturing tracks, where the ongoing digital transformation of domestic industries and manufacturing upgrades continuously generate new demand.

Gold stocks led the declines, with Lingbao Gold dropping more than 6%. Spot gold fell below the $3,800 per ounce mark for the first time since September 30, 2025. Recently, multiple Federal Reserve officials, including Dallas Fed President Logan, Fed Governor Waller, Kansas City Fed President Schmid, and Fed Governor Bowman, have all signaled a hawkish stance in their speeches, indicating that U.S. inflationary pressures remain stubborn and monetary policy still needs further tightening. According to CME's "FedWatch," the probability of a 25 basis point rate hike in December stands at 96.8%, while the probability of a 50 basis point hike is 3.2%.

Innovative drug concept stocks weakened, with Akeso Biopharma falling over 4%. The clinical trial of the company's core product AK112 (ivonescimab) for second-line treatment of epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer was officially rejected for approval by the U.S. Food and Drug Administration due to overall survival (OS) failing to meet the expected target. Institutional analysis suggests that the current HARMONi clinical trial's valuation contribution to AK112 is relatively limited, and the data performance of the subsequent HARMONi-3 trial will become the key to breaking through, though the specific timeline for that trial remains unclear.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment